TCON - Tracon Pharmaceuticals Inc Stock Price, Fair Value and News

1.70USD-0.18 (-9.57%)Market Closed

Market Summary

USD1.70-0.18

Market Closed

-9.57%

TCON Stock Price

View Fullscreen

TCON RSI Chart

TCON Valuation

Market Cap

3.9M

Price/Earnings (Trailing)

-1.08

Price/Sales (Trailing)

0.32

Price/Free Cashflow

1.05

TCON Price/Sales (Trailing)

TCON Profitability

Return on Equity

443.51%

Return on Assets

-35.51%

Free Cashflow Yield

95.04%

TCON Fundamentals

TCON Revenue

Revenue (TTM)

12.0M

Rev. Growth (Yr)

-52.63%

Rev. Growth (Qtr)

-100%

TCON Earnings

Earnings (TTM)

-3.6M

Earnings Growth (Yr)

106.27%

Earnings Growth (Qtr)

-95.92%

Breaking Down TCON Revenue

Last 7 days

-8.1%

Last 30 days

-80.2%

Last 90 days

-55.3%

Trailing 12 Months

-88.9%

How does TCON drawdown profile look like?

TCON Financial Health

Current Ratio

0.89

Debt/Equity

-11.24

Debt/Cashflow

0.4

TCON Investor Care

Shares Dilution (1Y)

91.01%

Diluted EPS (TTM)

-3.6

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	0	6.2M	9.1M	12.0M
2021	0	346.0K	346.0K	3.3M
2018	11.1M	10.5M	3.0M	3.0M
2017	2.9M	2.7M	9.4M	8.8M
2016	8.0M	4.6M	4.2M	3.4M
2015	4.4M	7.5M	7.5M	7.9M
2014	0	0	0	3.6M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Tracon Pharmaceuticals Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Nov 10, 2023	opaleye management inc.	sold	-129,448	0.2942	-440,000	-
Nov 10, 2023	opaleye management inc.	sold	-1,272,120	0.2942	-4,324,010	-
Oct 20, 2023	theuer charles	acquired	466	0.1333	3,500	president and ceo
Apr 27, 2023	theuer charles	bought	35,250	0.75	47,000	president and ceo
Apr 26, 2023	theuer charles	bought	2,639	0.66	3,999	president and ceo
Apr 20, 2023	theuer charles	acquired	481	0.1377	3,500	president and ceo
Apr 20, 2023	brown scott b.	acquired	481	0.1377	3,500	chief financial officer
Mar 09, 2023	opaleye management inc.	bought	240,821	1.38	174,508	-
Mar 01, 2023	theuer charles	bought	7,296	1.52	4,800	president and ceo
Feb 28, 2023	theuer charles	bought	304	1.52	200	president and ceo

Which funds bought or sold TCON recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 25, 2024	Bank of New York Mellon Corp	unchanged	-	2,613	4,409	-%
Apr 19, 2024	Cutler Group LLC / CA	sold off	-100	-	-	-%
Apr 12, 2024	Game Plan Financial Advisors, LLC	unchanged	-	255	430	-%
Mar 11, 2024	VANGUARD GROUP INC	reduced	-57.6	-64,303	46,011	-%
Feb 15, 2024	GTS SECURITIES LLC	new	-	2,764	2,764	-%
Feb 14, 2024	Ikarian Capital, LLC	unchanged	-	-8,021	484,244	0.04%
Feb 14, 2024	Royal Bank of Canada	reduced	-4.92	-	-	-%
Feb 14, 2024	MILLENNIUM MANAGEMENT LLC	new	-	33,523	33,523	-%
Feb 14, 2024	SUSQUEHANNA INTERNATIONAL GROUP, LLP	sold off	-100	-2,819	-	-%
Feb 14, 2024	BOOTHBAY FUND MANAGEMENT, LLC	unchanged	-	-750	45,324	-%

Are Funds Buying or Selling TCON?

Are funds buying TCON calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own TCON

No. of Funds

Unveiling Tracon Pharmaceuticals Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 05, 2024	ikarian capital, llc	5.9%	2,670,930	SC 13G/A
Mar 19, 2024	aaronson wayne	2.3%	716,925	SC 13G/A
Feb 14, 2024	lincoln park capital fund, llc	375%	116,821	SC 13G/A
Feb 09, 2024	opaleye management inc.	0.00%	10	SC 13D/A
Jun 02, 2023	lincoln park capital fund, llc	8.98%	2,369,821	SC 13G
Feb 14, 2023	ikarian capital, llc	12.5%	2,765,530	SC 13G/A
Feb 10, 2023	aaronson wayne	8.17%	1,778,453	SC 13G/A
Apr 29, 2022	aaronson wayne	7%	1,466,118	SC 13G
Feb 14, 2022	ikarian capital, llc	13.8%	2,691,110	SC 13G/A
Jan 27, 2022	linden capital l.p.	4.6%	921,603	SC 13G/A

Recent SEC filings of Tracon Pharmaceuticals Inc

View All Filings

Date Filed	Form Type	Document
Apr 12, 2024	S-1	Initial Public Offering
Apr 12, 2024	8-K	Current Report
Apr 12, 2024	424B5	Prospectus Filed
Apr 10, 2024	8-K	Current Report
Apr 08, 2024	8-K	Current Report
Apr 05, 2024	SC 13G/A	Major Ownership Report
Apr 03, 2024	8-K	Current Report
Mar 19, 2024	SC 13G/A	Major Ownership Report
Mar 13, 2024	4	Insider Trading
Mar 13, 2024	4	Insider Trading

Peers (Alternatives to Tracon Pharmaceuticals Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	42.1B	6.8B	3.52%	-17.31%	-8.94	6.15	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.1B	1.8B	-3.68%	-28.69%	-41.18	9.92	76.23%	61.08%
BMRN	15.3B	2.5B	-7.53%	-16.73%	74.64	6.2	13.74%	186.89%
INCY	11.7B	3.8B	-8.64%	-30.91%	15.68	3.1	8.58%	129.81%
MID-CAP
APLS	5.3B	396.6M	-24.84%	-46.72%	-10.08	13.43	425.83%	18.94%
BBIO	4.5B	-	-17.14%	78.66%	-6.9	60.35	54.84%	-34.79%
AXSM	3.5B	270.6M	-7.57%	4.22%	-14.61	12.91	440.80%	-27.84%
ARWR	2.8B	240.7M	-20.91%	-36.67%	-9.44	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-9.63%	-23.17%	-44.93	3.79	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-5.58%	-11.16%	24.84	4.45	85.90%	-14.05%
NVAX	606.0M	983.7M	-9.41%	-43.91%	-1.11	0.62	-50.36%	17.16%
CRBP	388.7M	881.7K	-5.61%	336.79%	-8.71	466.16	-77.61%	-5.33%
INO	267.6M	4.9M	-17.51%	25.55%	-1.98	54.99	-54.97%	51.71%
IBIO	6.0M	2.1M	-57.88%	56.88%	-0.22	2.14	-13.45%	66.37%

Tracon Pharmaceuticals Inc News

Latest updates

Tracon Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2021Q4	2021Q3	2021Q2	2018Q4	2018Q3	2018Q2	2018Q1	2017Q4	2017Q3	2017Q2	2017Q1	2016Q4	2016Q3	2016Q2	2016Q1	2015Q4	2015Q3	2015Q2
Revenue	-	3,045	-	9,000	4,500	-	346	-	-	-	3,000	-	7,498	631	626	617	815	807	1,210	1,395	1,180	4,197
Operating Expenses	66.1%	2,638	1,588	9,779	7,663	6,881	9,194	7,731	9,083	9,737	11,189	-	-	-	-	-	-	-	-	-	-	-
S&GA Expenses	-9.4%	1,144	1,262	1,916	4,599	4,151	6,126	1,800	2,107	1,622	1,751	-	-	-	-	-	-	-	-	-	-	-
R&D Expenses	-35.8%	1,494	2,326	3,488	3,064	2,730	3,068	5,931	6,976	8,115	9,438	-	-	-	-	-	-	-	-	-	-	-
Net Income	-95.9%	439	10,763	-6,286	-7,712	-6,952	-8,939	-7,756	-9,085	-9,754	-8,364	-	-	-	-	-	-	-	-	-	-	-
Net Income Margin	75.4%	-0.30*	-1.21*	-4.56*	-8.76*	-73.02*	-64.47*	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Free Cashflow	-103.5%	-522	15,048	-5,855	-5,123	-8,433	-4,200	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	7.4%	10,105	9,413	12,190	8,323	19,469	19,666	15,677	18,864	26,557	32,808	26,803	31,654	37,438	28,061	15,650	15,748	18,121	21,212	27,951	34,187	40,648
Current Assets	9.0%	9,090	8,340	10,991	7,139	18,228	18,020	14,156	17,293	24,936	31,142	26,189	31,217	36,914	27,453	14,956	14,969	17,260	20,270	26,930	33,088	40,603
Cash Equivalents	10.3%	8,564	7,763	1,735	6,610	17,433	17,212	13,580	16,640	24,072	29,901	25,580	26,408	32,131	26,451	14,453	14,134	16,412	19,053	26,336	22,085	25,136
Net PPE	-7.5%	37.00	40.00	44.00	47.00	51.00	51.00	50.00	49.00	50.00	49.00	40.00	18.00	16.00	13.00	16.00	19.00	23.00	27.00	32.00	38.00	45.00
Current Liabilities	-13.0%	10,182	11,702	27,073	14,182	22,371	11,760	12,063	14,953	13,676	12,734	14,888	10,280	10,543	9,953	9,235	8,772	11,834	12,830	13,939	13,554	13,495
Long Term Debt	-	-	-	-	-	-	9,095	-	-	-	-	-	698	1,391	2,079	2,761	3,438	2,739	3,402	4,057	4,704	5,343
LT Debt, Current	-	-	-	-	-	9,807	-	-	698	1,391	2,079	2,761	2,739	2,718	2,464	1,746	1,267	2,604	2,570	2,536	1,806	1,084
LT Debt, Non Current	-	-	-	-	-	-	9,095	-	-	-	-	-	698	1,391	2,079	2,761	3,438	2,739	3,402	4,057	4,704	5,343
Shareholder's Equity	-Infinity%	-809	-	-	-	-7,151	-	2,542	2,790	11,714	18,863	11,915	20,357	25,072	15,486	3,003	2,784	2,698	4,035	8,919	14,805	21,442
Retained Earnings	0.2%	-240,500	-240,900	-251,700	-245,400	-236,911	-229,914	-223,500	-217,200	-207,776	-200,100	-193,100	-184,173	-179,109	-174,798	-170,806	-166,355	-162,334	-158,398	-153,199	-146,873	-139,660
Additional Paid-In Capital	0.8%	239,646	237,823	235,935	234,319	229,737	227,257	226,000	220,019	219,471	218,908	205,011	204,515	204,166	190,270	173,801	169,134	165,028	162,403	162,088	161,648	161,099
Shares Outstanding	42.2%	2,213	1,557	1,331	1,201	1,156	1,023	997	980	863	826	775	774	-	-	-	-	-	-	-	-	-
Float	-	-	-	7,600	-	-	-	42,200	-	-	-	99,000	-	-	-	14,300	-	-	-	14,700	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-103.5%	-522	15,052	-5,851	-5,003	-4,653	-6,827	-8,017	-6,742	-5,114	-8,424	-4,174	-4,859	-3,626	-4,269	-3,855	-5,292	-4,243	-6,583	-5,773	-7,051	-8,126
Share Based Compensation	-0.6%	490	493	502	484	477	481	535	548	514	501	417	343	264	240	263	267	297	315	416	596	623
Cashflow From Investing	-	-	-	-	-	-4.00	-7.00	-2.00	-4.00	-9.00	-9.00	3,974	-4.00	-	-	-	-	-	-	10,000	4,020	5,054
Cashflow From Financing	114.6%	1,324	-9,091	1,048	-5,820	4,945	10,466	4,959	-686	-706	12,754	-628	-860	13,309	16,267	4,174	3,014	1,602	-700	24.00	-20.00	15.00

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

TCON Income Statement

2023-12-31

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Income Statement [Abstract]
Revenue	$ 12,045		$ 346
Revenue, Product and Service [Extensible Enumeration]	us-gaap:CollaborativeArrangementMember		us-gaap:CollaborativeArrangementMember
Operating expenses:
Research and development	$ 12,277	$ 13,888	$ 11,146
General and administrative	6,666	14,006	17,547
Arbitration success fees	2,375
Total operating expenses	21,318	27,894	28,693
Loss from operations	(9,273)	(27,894)	(28,347)
Other income (expense):
Interest expense, net	(7,304)	(994)	(318)
Other income (expense), net	12,989	(247)	(2)
Total other income (expense)	5,685	(1,241)	(320)
Net loss	$ (3,588)	$ (29,135)	$ (28,667)
Net loss per share, basic	$ (0.11)	$ (1.39)	$ (1.66)
Net loss per share, diluted	$ (0.11)	$ (1.39)	$ (1.66)
Weighted-average shares outstanding, basic	32,745,708	20,919,118	17,252,637
Weighted-average shares outstanding diluted	32,745,708	20,919,118	17,252,637

TCON Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 8,564,000	$ 17,433,000
Prepaid and other assets	526,000	795,000
Total current assets	9,090,000	18,228,000
Property and equipment, net	37,000	51,000
Restricted cash	73,000	67,000
Other assets	905,000	1,123,000
Total assets	10,105,000	19,469,000
Current liabilities:
Accounts payable	2,544,000	3,923,000
Accrued expenses	7,211,000	7,184,000
Accrued compensation and related expenses	427,000	1,457,000
Long-term debt, current portion		9,807,000
Total current liabilities	10,182,000	22,371,000
Other long-term liabilities	732,000	969,000
Arbitration financing payable	0	3,280,000
Commitments and contingencies (Note 5)
Stockholders’ equity (deficit):
Preferred stock, $0.001 par value, authorized shares - 10,000,000 at December 31, 2023 andDecember 31,2022; issued and outstanding shares - none
Common stock, $0.001 par value; authorized shares - 60,000,000 and 40,000,000 at December 31, 2023 and December 31, 2022, respectively; issued and outstanding shares - 44,269,976 and 23,125,250 at December 31, 2023 and December 31, 2022, respectively	44,000	23,000
Additional paid-in capital	239,646,000	229,737,000
Accumulated deficit	(240,499,000)	(236,911,000)
Total stockholders' deficit	(809,000)	(7,151,000)
Total liabilities and stockholders' deficit	$ 10,105,000	$ 19,469,000

About Tracon Pharmaceuticals Inc

TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of soft tissue sarcoma; and YH001, an investigational humanized CTLA-4 IgG1 monoclonal antibody for the treatment of various cancer indications. The company's clinical stage products also include TRC102, a small molecule that is in Phase II clinical trial for the treatment of mesothelioma, and in Phase I clinical trial to treat solid tumors and lymphomas, lung cancer, and glioblastoma; and TJ004309, a CD73 antibody that is in Phase I clinical development for the treatment of solid tumors. It has collaboration and license agreements with 3D Medicines Co., Ltd. and Jiangsu Alphamab Biopharmaceuticals Co., Ltd. for the development of envafolimab; I-Mab Biopharma for the development of CD73 antibody TJ004309; Case Western Reserve University for the development of TRC102; and cooperative research and development agreement with National Cancer Institute. The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005. TRACON Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in San Diego, California.

CEO	Dr. Charles P. Theuer M.D., Ph.D.
WEBSITE	traconpharma.com
INDUSTRY	Biotechnology
EMPLOYEES	18

Tracon Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for Tracon Pharmaceuticals Inc? What does TCON stand for in stocks?

TCON is the stock ticker symbol of Tracon Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Tracon Pharmaceuticals Inc (TCON)?

As of Tue Apr 30 2024, market cap of Tracon Pharmaceuticals Inc is 3.87 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of TCON stock?

You can check TCON's fair value in chart for subscribers.

What is the fair value of TCON stock?

You can check TCON's fair value in chart for subscribers. The fair value of Tracon Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Tracon Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for TCON so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Tracon Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether TCON is over valued or under valued. Whether Tracon Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Tracon Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for TCON.

What is Tracon Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Apr 30 2024, TCON's PE ratio (Price to Earnings) is -1.08 and Price to Sales (PS) ratio is 0.32. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. TCON PE ratio will change depending on the future growth rate expectations of investors.